For gene therapy, direct in situ correction of mutations in endogenous cellular genes would help achieve anatomically and temporally correct gene expression when compared to replacement gene therapy approaches that use viral vectors to introduce normal genes. On a genomic DNA level, different oligonucleotide (ODN) approaches have been used to correct mutated genes in their normal chromosomal location, including short single-stranded ODN containing complementary sequences, chimeric RNA/DNA ODN (RDO), and triple-helix-forming ODN. [1] [2] [3] However, the efficiency of these promising approaches has been variable and at times controversial. [4] [5] [6] [7] Consequently, new model systems that can assess gene targeting and correction in situ and be used to optimize ODN therapeutic approaches are needed. Herein, we describe the development and application of a gene targeting model, the XP-UVC selection assay, that can assess in situ gene correction of DNA repair genes in cells from patients with the autosomal recessive disease xeroderma pigmentosum (XP). 8 XP patients lack one of seven different types nucleotide excision repair (NER) genes and are not able to repair DNA damage induced by ultraviolet (UV) radiation including UV-induced photoproducts (cyclobutane pyrimidine dimers and 6-4 photoproducts). 9 This genomic damage results in a greater than 1000-fold increased incidence of skin cancers in XP patients. DNA repair genes provide a versatile cellular repair mechanism, able to repair a wide variety of DNA lesions (adducts, crosslinks, and breaks) that are caused by environmental or endogenous compounds and various types of radiation, and can interfere with the proper functioning of the genome. [10] [11] [12] [13] In the XP-UVC selection assay that we have developed, XP cell lines derived from XP patients are treated with the therapeutic ODN, such as the chimeric RDO, followed by exposure to UVC radiation (200-290 nm) in order to select for XP cells that contain corrected and functional NER genes. All XP cells that do not contain at least one genetically corrected NER allele should be killed by UV, while those XP cells with at least one corrected NER gene will survive.
14 Therefore, even if the percentage of XP cells corrected by the therapeutic ODN is low, we should be able to identify and enrich them and determine the correction frequency. Since the component proteins and enzymes of the NER are largely distinct from those of the mismatch repair mechanisms presumably utilized by ODN to correct endogenous gene mutations in situ, the NER-deficient cells from XP patients should still be able to execute mismatch repair of point mutations following ODN treatment. 2 In our XP-UVC selection assay described here, selective UV pressure is applied to immortalized cells (EBV-transformed lymphoblasts) containing a defined mutation in the XPA gene that encodes a major component of the NER system. 15, 16 The mutations in both XPA alleles of XP12BE, the patient we tested, are single point mutations that interfere with correct splicing of the XPA transcript. [17] [18] [19] One mutation is a G to T transversion (father) at the intron 3 splice acceptor site, while the other mutation is G to C transversion (mother) in the splice donor sequence of exon 4 ( Figure 2a) . In this report, we first demonstrate that UVC can be used to select XP lymphoblasts possessing increased DNA repair ability and then define the assay sensitivity for detection of corrected XP cells that contain at least one normal XPA allele.
The first requirement was to develop a sensitive assay for detecting XP lymphoblasts containing one (or more) corrected XPA genes. We have established an assay of lymphocyte UVC survival by exposing the lymphocytes to different UVC doses. 20, 21 The optimal UVC selection dose for XP patients' cells that contain mutations in different NER genes was determined in a similar manner. As shown in a representative experiment (Figure 1a) , surviving XP patient's lymphocytes cannot be detected following a UVC dose of 60 s duration (7.56 J/m 2 ) or greater, while parental lymphoblasts (containing one normal XPA allele) will survive UVC doses of 60 s or more (Figure 1b) . At this UVC dose, XPA lymphoblasts corrected by ODN treatment should survive, proliferate, and expand while all the uncorrected XPA lymphoblasts will die. When survival curves are extrapolated back to the y-axis (Figure 1a and c) , an ability to detect approximately one surviving cell for every 100 UVCirradiated cells is indicated (2-5 Â 10 3 out of 2 Â 10
5
). The sensitivity of our assay could also be determined by measuring the minimal number or percentage of corrected XPA lymphoblasts that could be detected. To A 312 bp region of XPA exon 4 was PCR amplified using intronic primer pair 41 and 42 as described, 22 digested with the restriction endonucleases Hpy188I or AflIII (NEN Biolabs Inc.), and the products were displayed on a 2% agarose gel stained with ethidium bromide. Hpy188I cuts the PCR product at two points yielding three fragments (181, 71, and 60 bps), whereas the G to T mutation (father and patient) at the intron 3 splice acceptor site disrupts this Hpy188I site, generating two fragments (181 and 131 bps). In the mother and patient, the G to C transversion at the 3 0 -end of exon 4 creates an AflIII restriction site in the PCR product yielding two fragments (236 and 76 bps), while normal PCR fragments have a single band of 312 bp. Lanes 1 and 2, DNA from normal fibroblast (AG05186); lanes 3 and 4, DNA from the patient; lanes 5 and 6, DNA from the father; Lanes 7 and 8, DNA from the mother undigested and digested with Hpy188I, respectively; lanes 9-16, showing the PCR products undigested and digested with AflIII; lane 17, marker, 1 kb plus DNA ladder (Invitrogen). The RFLP indicates the presence of a normal and mutant allele in parental DNA, while both mutant inherited alleles are present in patient DNA.
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A Terunuma et al determine assay sensitivity, varying percentages of the parental lymphoblasts (10, 1, 0.1, 0.01, and 0.001%) were combined with the XPA (XP12BE) lymphoblasts and UVC selection was applied (Figure 1c ). Parental lymphoblasts were detected when initially present as 1% of XPA lymphoblasts, but could not be detected at 0.1% or lower ( Figure 1c ). One advantage of the XP-UVC selection assay is that it can demonstrate correction of an XPA gene on both a functional and genomic level. In surviving XPA lymphoblasts, correction of XPA point mutations can be confirmed by direct sequencing of genomic DNA from individual clones of UVC-resistant XPA lymphoblasts obtained by limiting cell dilution. Additionally, in XPA patient XP12BE, the father's G to T transversion at the intron 3 splice acceptor site removes a Hpy188I restriction enzyme site and the mother's G to C transversion in the exon 4 splice donor site creates a new AflIII site ( Figure  2a) , allowing individual clones of UVC-resistant lymphoblasts to be assessed for the presence of these restriction sites (Figure 2b) .
In a pilot experiment, we assessed the ability of chimeric RDO to correct XPA splice site mutations and restore NER function and increase UVC resistance. Chimeric RDO that are designed to target and correct single base-pair mutations in endogenous genes contain correct sequences that are homologous to the mutated endogenous gene sequences. 2, 23, 24 In the homologous chimeric RDO sequences, 10 RNA bases flank five center DNA bases, with one DNA base mismatched for the point mutation. 2, 23, 24 When the chimeric RDO base pair with the homologous mutated endogenous gene, the mismatch created between the chimeric RDO (DNA strand) and the mutated endogenous gene at the point mutation site creates a structural distortion that is presumably recognized by the cellular mismatch repair machinery. Although the mechanism remains uncertain, the chimeric RDO may promote the crucial first step of homologous pairing (promoted by endogenous recombinases) with the target sequence, thereby increasing the probability of mismatch repair. 25 Although this approach has generated much interest as a potential ex vivo gene therapy approach for in situ correction, a range of gene correction frequencies have been reported (from 0.003% or less, up to 60%). [2] [3] [4] 6, 7, [26] [27] [28] [29] Chimeric RDO homologous to the mother's XPA exon 4 splice donor mutation were first constructed as previously described (Figure 3a) . In order to deliver as much RDO into lymphocytes as possible without harming their growth/survival characteristics, FITC-labeled chimeric RDO were used to determine the optimal delivery method. Cationic lipids such as DOTAP (30 ml DOTAP plus 5 mg ODN) were superior to other methods such as electroporation and were able to transfect approximatetly 35% of lymphocytes as shown by FACS analysis (data not shown). In the UVC selection protocol (Figure 3b) , lymphocytes in log-phase growth were exposed to chimeric RDO (XP2a and control XP2b) for 6-18 h. After a period of 10-14 days to allow gene conversion and expression of a normal XPA protein, XP lymphoblasts and controls were exposed to a UVC dose of 60 s or 7.56 J/m 2 inside an enclosed UVC apparatus. In one successful experiment, approximately 1% of UVC-irradiated XP lymphoblasts treated with the XP2a RDO survived at 10 days (5/5 flasks) compared with nonirradiated controls, while no XP lymphoblasts treated with control XP2b RDO survived UVC selection (data not shown). In order to further enrich for XPA-corrected cells by additional UVC selection, the surviving XP lymphoblasts were subcultured and exposed to a second UVC dose of varying amounts XP-UVC selection assay to optimize ODN correction A Terunuma et al XP lymphoblasts that contain corrected XPA genes should possess functional NER. To determine if the surviving cells in the XP-UVC assay possess NER activity, we used a functional assay in which UVCirradiated CAT expression plasmids are transfected into XP and normal lymphoblasts, and the ability of these cells to repair the UVC-induced DNA damage and restore CAT expression activity is measured. 30 The XP lymphoblasts treated with the XP2a RDO had greater ability to repair UVC-induced DNA damage and restore Figure 5 Confirmation of genomic correction using PCR-RFLP analysis and genomic sequencing of UVC-resistant lymphoblast clones. (a) Lymphoblasts that survived two cycles of UVC exposure were separated into individual clones, and confirmed for their genomic correction by PCR-RFLP analysis similar to Figure 2b . A 340-bp PCR product from the mutant allele was digested with AflIII into 237-and 103-bp fragments, while those from the wild-type allele were not digested. Only clones #3 and #9 demonstrated resistance to AflIII digestion, indicating correction to wild type, while eight other clones were digested with AflIII. (b) Genomic samples of each indicated cell type was amplified by PCR and subjected to genomic sequencing. The arrow indicates the site of mutation at the end of exon 4. While samples from the mother and the patient showed mutated sequence (top and middle, respectively), a sample from corrected clone #9 showed wild-type genomic sequence (bottom). It is to be noted that the shown sequences are antisense. Figure 4 The DNA repair activity is assessed by a functional post-UV host cell reactivation (HCR) study. HCR was employed to measure the DNA repair ability of the cell line from a normal donor and from an XP patient with or without treatment with RDO (XP2a). The cells were transfected with a UV-treated plasmid (pRSVcat) expressing the chloramphenicol acetyl transferase (CAT) gene and CAT activity was measured after 48 h as described previously. 31 Unrepaired photoproducts in the plasmid DNA inhibit transcription of the cat gene. Repair of the photoproducts occurs in a process that depends on the cellular DNA repair system. DNA repair capacity was expressed as a percentage of CAT activity obtained from UV-treated plasmid compared with the control untreated plasmid. The post-UV relative CAT expression was considerably higher in the normal cells than in the cells from the patient. The lower CAT activity indicates defective repair of the UV damage in pRSVcat by cells from the XP patient. In contrast, patient cells treated with the XP2a RDO showed an intermediate CAT activity. This indicates that RDO treatment partially corrected the targeted genetic defect. Each data point represents an independent transfection.
A Terunuma et al CAT expression activity to the plasmid than XP lymphoblasts treated with control XP2b RDO. However, they had less post-UV CAT activity than normal or parental lymphoblasts (XPA+/+ or XPA+/À). This suggests that the RDO procedure induced some degree of functional restoration of XPA activity in XP2a RDO-treated cells (Figure 4) . In order to confirm genomic correction of XPA mutations by clonal analysis, XPA lymphoblasts that had survived two rounds of UVC selection were separated into individual clones by limiting cell dilution. PCR-RFLP analysis to determine the presence or absence of an AflIII restriction site was performed on 10 clones (Figure 5a ). Only lymphocyte clones #3 and #9 lost the AflIII restriction site, indicating a correction of the XPA mutation in 2/10 clones (Figure 5a) . Correction of the XPA mutation was confirmed by sequence analysis of both clones (Figure 5b and data not shown). It is theoretically possible that the small number of partially 'corrected' patient cells could represent contaminating cells from the father since these cells also would lack the mother's mutation and would have normal UVC sensitivity. Since the XP patient is female, we assessed contamination by testing for the presence of TDF, a testisdetermining factor on the Y chromosome (GenBank accession number: G28582). We used PCR-based amplification of the TDF region of the Y chromosome. The characteristic 210 bp band was found with DNA from the father and was not observed in DNA from the patient, her mother or from the corrected cells (data not shown). These findings rule out male cell contamination as an explanation for the observation of XPA corrected clones. It also should be noted that XP lymphoblasts treated with control RDO (XP2b) did not survive UVC selection, which should rule out a nonspecific RDO effect or problems with the UVC selection assay, and indicates an effect associated with XP2a RDO treatment. Since the rate of XPA gene correction by RDO is low (o2 Â 10
À5
) and not readily reproducible, it will be difficult to adequately study and understand this variability. Importantly in these studies, RDO treatments were only demonstrated to correct an XPA mutation in one experiment despite additional attempts with carefully controlled experimental conditions. Additionally, no documented correction of XPA mutations was demonstrated after only one UVC selection. The calculated efficiency of RDO correction in the one successful experiment described above was no greater than 1 Â 1 Â 20% or no greater than a frequency of 2 Â 10
. Finally, multiple attempts to correct the XPA mutation inherited from the father (intron 3 splice acceptor site) were also unsuccessful.
The XP-UVC selection model to assess correction of XPA mutations has several important advantages. It allows one to optimize direct ex vivo gene correction by ODN in different tissues and cell types that contain an XPA mutation. This is important because each tissue and cell type may have distinct requirements for gene delivery, homologous pairing, and mismatch repair. Although lymphocytes were chosen in these studies, UVC selection could also be applied to other XP (XPAÀ/À) cell types such as keratinocytes and fibroblasts, or any other cell type easily obtained from donors. Additionally, transgenic knockout mouse models that lack XP genes could be an important source for different cell types for gene-targeting studies. This would help address one of the problems of ODN-mediated gene repair, its variability in different cells and tissues. Since the XP-UVC selection assay enriches for corrected cells, it should be quite useful to study low-frequency gene correction mechanisms, such as the RDO-mediated correction described above. With ODN therapeutic approaches such as RDO, clonal analysis of corrected cells is very important to ensure that nonartifactual gene correction is present, and as demonstrated here, UVC selection is adaptable to clonal analysis.
One question that remains to be answered is why XPA mutations were successfully corrected in only one experiment. This result is similar to the variability reported by other investigators and may reflect the sensitivity of our assay. In the unsuccessful experiments, the XPA correction efficiency/frequency may have been below the level of detection so that no surviving cells were detected following UVC selection. Another question is why most of the XP2a-treated XP lymphoblasts that survived the first UVC treatment were unable to survive a second UVC dose. This result could indicate that only a small percentage of the initial UVC survivors had permanent or stable XPA gene correction and suggests that the majority of XP cells surviving the first UVC dose had only a transient functional correction of XPA activity that was associated with XP2a RDO treatment. The functional NER assay also demonstrates that a percentage of these cells possessed the functional ability to repair UVC damaged plasmids. Regarding the clonal analysis, it is not clear why only 2/10 or 20% of XP lymphoblasts surviving the second UVC dose had documented XPA gene correction.
The XP-UVC selection assay can be used to optimize other types of ODN therapeutic approaches. For gene therapy purposes, a future goal would be to correct endogenous NER alleles in keratinocytes from an XP patient, amplify the corrected cells in culture, and graft them back onto the same patient, where they should have a strong growth advantage compared to XP (XPAÀ/À) keratinocytes.
